Cart
sales@molnova.com
PHA767491 HCl
CAS No. 942425-68-5
PHA767491 HCl( CAY-10572 hydrochloride )
Catalog No. M19277 CAS No. 942425-68-5
PHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 46 | In Stock |
|
| 5MG | 41 | In Stock |
|
| 10MG | 58 | In Stock |
|
| 25MG | 93 | In Stock |
|
| 50MG | 133 | In Stock |
|
| 100MG | 219 | In Stock |
|
| 200MG | 324 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePHA767491 HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionPHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM).
-
DescriptionPHA-767491 is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and MK2, 100-fold selectivity against CHK2 and PLK1.
-
In Vitro——
-
In Vivo——
-
SynonymsCAY-10572 hydrochloride
-
PathwayEndocrinology/Hormones
-
TargetReductase
-
RecptorCdk1| Cdk2| Cdk9| Cdc7| GSK-3β
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number942425-68-5
-
Formula Weight213.24
-
Molecular FormulaC12H11N3O
-
Purity>98% (HPLC)
-
SolubilityDMSO : 17.33 mg/mL 69.40 mM
-
SMILESCl.O=C1NCCc2nc(cc12)c3ccncc3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Montagnoli A, et al. Nat Chem Biol, 2008, 4(6), 357-365.
molnova catalog
related products
-
Lidorestat
Lidorestat (IDD-676) is an aldose reductase inhibitor (IC50: 5 nM) with effective, selective and oral activity. Lidorestat improves nerve conduction and reduces the formation of cataracts.
-
Alrestatin
Alrestatin is a specific inhibitor of aldose reductase and attenuates glucose-induced angiotensin II production in rat vascular smooth muscle in vitro.
-
Ponalrestat
ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice
